On initiation or discontinuation of guselkumab in patients that are getting concomitant CYP450 substrates, particularly those with a narrow therapeutic index, consider monitoring for therapeutic effect. Monitor Carefully (1)methylphenidate transdermal will enhance the level or effect of phenobarb